AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 271 min read$ACAD

Kihara James sold $114K of ACAD

Kihara James (PRINCIPAL ACCOUNTING OFFICER) sold 5,401 shares of ACADIA PHARMACEUTICALS INC (ACAD) at $21.18 ($0.11M total) on 2026-05-26.

Original reporting
SEC EDGAR · Kihara James
Published May 27, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ACAD
Neutral
medium confidence
Mentioned
$ACAD
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACADNeutralLow
01

Why it matters

Insider sales can influence short-term sentiment, but without concurrent company catalysts (earnings, trial results, regulatory actions), the trading signal is typically low-confidence.

02

Market read

Traders may monitor for follow-on insider activity, but this single, small sale is unlikely to drive a sustained repricing absent other news.

03

What to watch

No 10b5-1 plan is indicated, but the article provides no context on compensation, tax obligations, or prior sale cadence; without trend data, inference is weak.

Relevance 6/10Timing: Immediate (new SEC Form 4 filing on 2026-05-27) but limited catalyst strength.

Background

The article is a SEC Form 4 insider transaction disclosure for Acadia Pharmaceuticals, showing an open-market sale by the principal accounting officer.

Company-level read

Ticker impact

$ACADNeutralMedium confidence
Context

Acadia Pharmaceuticals officer Kihara James sold 5,401 shares in an open-market transaction worth about $114.4K, disclosed via SEC Form 4.

Expected impact

Likely limited near-term impact; any move would be modest and sentiment-driven rather than thesis-changing.

Evidence & confidence

The filing is an ownership-change disclosure without accompanying company-specific news (no earnings, trial, deal, or guidance). The sale size is relatively small versus typical market float, and there is no stated 10b5-1 plan.

Market effects

Sector

Minimal; insider selling in a single biotech does not reliably reset sector expectations without additional operational/regulatory catalysts.

Regional

None indicated beyond routine US biotech sentiment.

Global

None indicated; filing is US insider disclosure only.

Counterpoint

What could challenge this read

The sale could be routine liquidity/portfolio management rather than a bearish signal, especially since the filing lacks any stated negative company event.

Key entities

  • issuer
    ACADIA PHARMACEUTICALS INC

    Subject of the insider transaction disclosure; officer sold 5,401 shares for ~$114.4K.

  • insider
    Kihara James

    Principal Accounting Officer who executed the open-market sale disclosed in the Form 4.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACAD insider trading history →

Related articles

SEP 25
$ACADMedAI 8/10

ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets

Acadia Pharmaceuticals (ACAD) stock fell 5% after analysts cut price targets following Phase 2 RADIANT trial results for Remlifanserin in Alzheimer's disease psychosis. The trial missed the primary endpoint but showed promise in a subgroup. Analysts from Needham, Deutsche Bank, BMO Capital, and Citizens lowered targets but maintained positive ratings, citing future potential.

stocktwits.com2 min
SEP 25
$ACADHighAI 8/10

ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13%

ACADIA Pharmaceuticals (ACAD) shares fell 13% after Goldman Sachs initiated a 'sell' rating and $17 price target due to weak phase 2 trial results for remlifanserin. Citi and BMO Capital maintained positive ratings but lowered price targets. The company plans to present detailed results at an upcoming conference. Hedge funds increased holdings in Q2, with 38 funds holding positions.

finance.yahoo.com2 min
SEP 24
$ACADMedAI 8/10

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease…

ACADIA PHARMACEUTICALS INC (ACAD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) — Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 develop

SEC EDGAR 8-K2 min
SEP 24
$ACADMedAI 8/10

BMO cuts Acadia Pharmaceuticals stock price target on trial miss

BMO Capital reduced its price target for Acadia Pharmaceuticals (ACAD) to $34, citing a trial miss, but maintained an Outperform rating. The stock is down 7.4% over the past week. The firm lowered the success probability for the drug candidate to 35% from 40%. Acadia generated $1.14 billion in revenue over the last twelve months and has a market cap of $3.93 billion.

investing.com2 min